Trump administration will fund new research on controversial psychedelic drug ibogaine

Trump administration will fund new. Trump administration will fund new research on controversial psychedelic drug ibogaine.

ScienceNews Info Wire5 min read
Trump administration will fund new research on controversial psychedelic drug ibogaine

Trump administration will fund new. Trump administration will fund new research on controversial psychedelic drug ibogaine.

Article outline

  1. What happened
  2. What comes next
  3. Background
  4. Official response
  5. The key numbers
  6. The bottom line

Key points

  • Kennedy Jr., testifies during a House Energy and Commerce Committee, Tuesday, June 24, 2025, in Washington.
  • Denise Jones Gregory is the first female alum president of the almost 150-year-old institution.
  • Three applications for psychedelics are pending review at the Food and Drug Administration.
  • Trump's order on psychedelics came after podcaster Joe Rogan remarked he texted Trump concerning ibogaine.
  • The effort confirmed Thursday includes almost $5 million to lay the groundwork for U.S.

Secretary of Health and Human Services Robert F. Kennedy Jr., testifies during a House Energy and Commerce Committee, Tuesday, June 24, 2025, in Washington. (AP Photo/Mariam Zuhaib).

Notably, the effort confirmed Thursday includes almost $5 million to lay the groundwork for U.S. Studies of ibogaine. Veterans groups contend ibogaine has great promise for hard-to-treat conditions like post-traumatic stress disorder, severe depression and opioid addiction.

WASHINGTON (AP) – Federal authorities on Thursday unveiled new funding to explore the medical potential of ibogaine, a controversial psychedelic drug championed by veterans, conservative lawmakers and podcasters aligned with President Donald Trump.

Health Secretary Robert F. Kennedy Jr. Remarked his department is awarding up to $4.9 million to prepare for the first U.S. Studies of ibogaine for post-traumatic stress disorder, a hard-to-treat condition linked to higher suicide and substance abuse rates among veterans.

In practice, the funds will not go directly to patient research, Kennedy stated, but to lay the groundwork needed to manufacture, dose and design studies of the drug.

Ibogaine is created from a shrub native to West Africa. It can cause intense hallucinations, nausea, vomiting, tremors and sometimes deadly irregular heart rhythms. Ibogaine is at present illegal, in the same ultra-restrictive class as LSD, ecstasy and most other psychedelic drugs.

Veterans organizations and psychedelic advocates contend that ibogaine has great promise for intractable conditions such as PTSD, severe depression and opioid addiction. U.S. Research on the drug has essentially been frozen for decades due to ibogaine's restricted status.

Kennedy remarked the administration will receive data and treatment guidance from Beond Inc., a Texas-based firm that has treated more than 3, 000 patients with ibogaine in Mexico, where the drug is not illegal.

"That is going to allow us to dramatically accelerate the clinical trial process, " Kennedy remarked. "We're going to have, I think, a record drug approval process." Extra funding awards may explore ibogaine's apply for addiction, he noted.

Veterans Affairs Secretary Doug Collins. This person joined Kennedy for the announcement, remarked the collaborative effort would focus first on safety and "best-in-class research."

"For veterans living with PTSD, we owe them both urgency and the best science we can produce, " Collins remarked.

Kennedy and Collins have previously voiced backing for the potential of psychedelics, citing the experiences of veterans who have traveled abroad for therapy with ibogaine and other mind-altering substances.

When Trump signed an executive order directing federal agencies to speed up review and research of psychedelics that could support with mental health conditions, thursday's announcement was previewed in April.

Three applications for psychedelics are pending review at the Food and Drug Administration. They include the first potential medicines created from psilocybin, the active ingredient in magic mushrooms, and MDMA, additionally called ecstasy. Decisions on those drugs could come within weeks or months. Since of its safety risks, ibogaine research has moved more gradually.

Meanwhile, the little data at present available mostly comes from patients who have traveled to Mexico or other countries where ibogaine is not heavily regulated. Ibogaine clinics typically charge $10, 000 to $20, 000 for one course of treatment. It often involves monitoring of a patient's heart readings while emergency medical workers are on standby.

Trump's order on psychedelics came after podcaster Joe Rogan remarked he texted Trump concerning ibogaine. It he repeatedly has discussed on his show. According to Rogan, the president rapidly responded: "Sounds great. Do you want FDA approval? Let's do it." Regarding the Author(s). Matthew Perrone, Associated Press. News Jeremy Pittari November 11, 2026. Inauguration ceremony set for JSU's 14th president.

Dr. Denise Jones Gregory is the first female alum president of the almost 150-year-old institution. More From This Author. DC Matthew Perrone, Associated Press July 29, 2025.

US health authorities crack down on kratom-related products after complaints from supplement industry. News Frank Corder November 12, 2026.

Mississippi Forward PAC among groups backing Democrats named in FEC complaint filed by nonpartisan watchdog. News Magnolia Tribune November 11, 2026. Magnolia Mornings: November 11, 2026.

Significant state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion to start your day informed. News Kevin Freking, Associated Press November 10, 2026.

Rep. Jim Jordan of Ohio elected to lead House Republicans in the minority.

Jordan, who serves as chairman of the House Judiciary Committee, defeated Rep. Steve Scalise of Louisiana in a secret ballot election of Republicans who will serve in the next Congress. The vote was 106-73. News Magnolia Tribune November 12, 2026. Magnolia Mornings: November 12, 2026. News Frank Corder November 11, 2026. Senator-elect: Colom wins Mississippi U.S. Senate race. News Christopher Rugaber, Associated Press November 11, 2026.

As higher rates seep into broader economy, Fed office-holders consider faster hikes. Business Cass Rutledge November 10, 2026. Universal Services expanding operations in Leakesville. Business Frank Corder November 10, 2026. Ingalls, SUPSHIP break ground on new $50 million facility in Pascagoula. Business Cass Rutledge November 9, 2026. Jabil is hiring more than 300 in Byhalia. Culture Alistair Begg November 12, 2026. Culture Meredith Biesinger November 11, 2026. Chimneyville Arts Festival Celebrates 50 years of Mississippi crafts. Culture Alistair Begg November 11, 2026. Opinion Russ Latino November 11, 2026. Notably, the debt we owe on Veterans Day.

Opinion Sid Salter November 11, 2026. Partisan realignment in Congress reshuffles Mississippi's influence in Washington. Opinion Dr. Tom Miller, Jr. November 10, 2026.

Access to banking is a national difficulty so it needs a national solution.

In short, trump administration will fund new research on controversial psychedelic drug ibogaine is the central thread here, and readers can expect follow-up reporting as the picture becomes clearer.

Leave a Reply

Your email address will not be published. Required fields are marked *